Portfolio
Cutiss is a Swiss clinical-stage life-science company that provides patients with acute scarring (especially due to burns, trauma and operations) with bio-engineered, customised human skin (their trademarked “denovoSkin”).
Visit Website ImmonuPhotonics is a biotechnology company that is developing a proprietary treatment for solid-tumour cancers. The company is headquartered in St Louis, Missouri, USA, with subsidiaries in Bern, Switzerland, and Tianjin, China.
Visit Website
Biograil’s novel technology allows for the oral delivery of injectable pharmaceutical products.
Visit WebsiteLatest News Articles
Positive Phase 2 trial interim analysis on safety and efficacy for denovoSkin™ in pediatric burn patients
CUTISS has completed an interim analysis in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in c
EMA authorizes Phase 3 clinical trial for denovoSkin™
CUTISS has received authorization from the European Medicines Agency (EMA) to commence the Phase 3 clinical trial for our lead
Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville
Immunophotonics, Inc., in collaboration with Dr. Robert CG Martin II, M.D, PhD, FACS, who serves as the Principal Investigator
